PLX EBITDA Margin
Protalix Biotherapeutics Inc · EBITDA Margin
PLX EBITDA Margin
Latest reported32.60%period ending
PLX TTM EBITDA Margin (-26.29% → 32.60%)
TTM ebitda margin
High-resolution chart · PNG
PLX ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| 32.6015% | |
| 29.2311% | |
| -5.2916% | |
| 14.3451% | |
| 17.032% | |
| 11.9821% | |
| 12.21% | |
| -14.1787% | |
| -31.2722% | |
| 18.324% | |
| 19.7652% | |
| 25.1458% | |
| 21.1938% | |
| -27.6853% | |
| -22.6311% | |
| -27.6708% | |
| -26.4343% | |
| -37.8499% | |
| -46.8162% | |
| -20.4438% | |
| -22.3538% | |
| -7.3328% | |
| 7.0749% | |
| 6.594% | |
| 7.9031% | |
| 2.3035% | |
| -15.8942% | |
| 0.8929% | |
| -2.3211% | |
| -4.093% | |
| -3.8692% | |
| -109.1796% | |
| -157.8356% | |
| -97.3692% | |
| -375.9277% | |
| -361.1329% | |
| -416.9459% | |
| -701.5251% | |
| -332.3622% | |
| 816.2374% | |
| 1,095.4154% | |
| 820.8458% | |
| 1,077.165% | |
| -198.606% | |
| -262.9018% | |
| -220.2556% | |
| -143.2586% | |
| -165.888% | |
| -165.567% | |
| -171.3625% | |
| -202.9011% | |
| -223.2877% | |
| -186.1427% | |
| -19.4034% | |
| -24.634% | |
| -19.4839% | |
| -31.9581% | |
| -356.7869% | |
| -268.2589% | |
| -405.1587% | |
| -278.1823% | |
| -280.3756% | |
| -534.6131% | |
| -559.9248% | |
| -1,359.0637% | |
| -2,146.6318% | |
| -7,726.5464% | |
| -18,747.3333% | |
| -16,246% | |
| -12,382% | |
| -10,975.3333% | |
| -32,058,700% | |
| -29,178,700% | |
| -35,554,300% | |
| -15,622,100% | |
| -16,260,000% | |
| -12,718,533.3333% | |
| -551.8703% | |
| -302.1248% | |
| -50.9342% | |
| -18.3679% | |
| -21.5597% | |
| -9.5324% | |
| -7.0774% | |
| -11.4428% | |
| -6.1303% | |
| -26.2931% |